Trial Profile

Safety and Efficacy Study of NWRD09 in HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NWRD-09 (Primary)
Indications Adenocarcinoma; Cervical cancer; Cervical intraepithelial neoplasia; Squamous cell cancer; Vaginal intraepithelial neoplasia; Vulvar intraepithelial neoplasia
Focus Adverse reactions
Sponsors Newish Technology (Beijing)

26 Dec 2024 According to Novi Biotech media release, Company expects to submit a new drug clinical research approval application to the National Medical Products Administration in the near future, and hopes to obtain an implicit license for the new drug clinical trial application in early 2025
26 Dec 2024 According to Novi Biotech media release, Novi Biotech is recruiting third-party Contract Research Organizations (CROs) to support the trial
26 Dec 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com